Compare ROIV & ATI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROIV | ATI |
|---|---|---|
| Founded | 2014 | 1960 |
| Country | United Kingdom | United States |
| Employees | N/A | 7600 |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2B | 24.2B |
| IPO Year | 2021 | 1996 |
| Metric | ROIV | ATI |
|---|---|---|
| Price | $34.90 | $187.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $28.94 | ★ $153.75 |
| AVG Volume (30 Days) | ★ 5.8M | 1.7M |
| Earning Date | 05-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.76 |
| EPS | N/A | ★ 0.85 |
| Revenue | $8,260,000.00 | ★ $4,043,500,000.00 |
| Revenue This Year | N/A | $9.52 |
| Revenue Next Year | $744.61 | $9.02 |
| P/E Ratio | ★ N/A | $221.09 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.71 | $70.42 |
| 52 Week High | $35.90 | $205.31 |
| Indicator | ROIV | ATI |
|---|---|---|
| Relative Strength Index (RSI) | 71.26 | 50.52 |
| Support Level | $26.65 | $139.22 |
| Resistance Level | N/A | $205.31 |
| Average True Range (ATR) | 1.17 | 6.97 |
| MACD | 0.39 | -2.01 |
| Stochastic Oscillator | 82.59 | 17.30 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.